This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brezak, M.-C. Articles by Ducommun, B. Search for Related Content PubMed PubMed Citation Articles by Brezak, M.-C. Articles by Ducommun, B.

¹ IPSEN, Institut Henri Beaufour, Les Ulis, France; ² Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération-Centre National de la Recherche Scientifique, UMR5088-IFR109 "Institut d'Exploration Fonctionnelle des Génomes," Université Paul Sabatier, Toulouse, France; ³ Cellis Pharma, Saint Malo, France; and ⁴ IPSEN, Biomeasure, Milford, Massachusetts

Requests for reprints: Bernard Ducommun, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération-Centre National de la Recherche Scientifique, UMR5088, 118 route de Narbonne 4R3B1, 31062 Toulouse, France. Phone: 33-5-6155-8110; Fax: 33-5-6155-8109. E-mail: ducommun{at}cict.fr

Cell cycle regulators, such as the CDC25 phosphatases, are potential targets for the development of new anticancer drugs. Here we report the identification and the characterization of BN82685, a quinone-based CDC25 inhibitor that is active in vitro and in vivo. BN82685 inhibits recombinant CDC25A, B, and C phosphatases in vitro. It inhibits the growth of human tumor cell lines with an IC₅₀ in the submicromolar range, independently of their resistance to chemotherapeutic agents. This inhibitory effect is irreversible on both the purified CDC25 enzyme in vitro and on tumor cell proliferation. The specificity of BN82685 towards the CDC25 phosphatases is shown by an increase in cyclin-dependent kinase 1 tyrosine 15 phosphorylation, by the reversion of the mitosis-inducing effect of CDC25B overexpression in HeLa cells, and by the lack of a growth inhibitory effect in an assay based on the use of a CDC25-independent fission yeast model. Finally, when administered p.o., BN82685 is shown to inhibit the growth of the human pancreatic tumor Mia PaCa-2 xenografted in athymic nude mice. BN82685 is therefore a promising new compound targeting CDC25, which confirms the interest of the inhibition of these enzymes as an anticancer therapeutic strategy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: M-C. Brezak and M. Quaranta contributed equally to this work.

Received 5/23/05; revised 6/25/05; accepted 7/15/05.

This article has been cited by other articles:

				C. Stolfi, D. Fina, R. Caruso, F. Caprioli, M. C. Fantini, A. Rizzo, M. Sarra, F. Pallone, and G. Monteleone Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase Carcinogenesis, June 1, 2008; 29(6): 1258 - 1266. [Abstract] [Full Text] [PDF]

				D. Ray, Y. Terao, D. Nimbalkar, H. Hirai, E. C. Osmundson, X. Zou, R. Franks, K. Christov, and H. Kiyokawa Hemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice Cancer Res., July 15, 2007; 67(14): 6605 - 6611. [Abstract] [Full Text] [PDF]

				M. Cazales, R. Boutros, M.-C. Brezak, S. Chaumeron, G. Prevost, and B. Ducommun Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly Mol. Cancer Ther., January 1, 2007; 6(1): 318 - 325. [Abstract] [Full Text] [PDF]

				A. Fernandez-Vidal, L. Ysebaert, C. Didier, R. Betous, F. De Toni, N. Prade-Houdellier, C. Demur, M.-O. Contour-Galcera, G. P. Prevost, B. Ducommun, et al. Cell Adhesion Regulates CDC25A Expression and Proliferation in Acute Myeloid Leukemia. Cancer Res., July 15, 2006; 66(14): 7128 - 7135. [Abstract] [Full Text] [PDF]

				B. Bugler, M. Quaranta, B. Aressy, M.-C. Brezak, G. Prevost, and B. Ducommun Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol. Cancer Ther., June 1, 2006; 5(6): 1446 - 1451. [Abstract] [Full Text] [PDF]